fda regulations on tirzepatide Is a Stimulant? Mechanism and Safety Profile FDA says shortage of GLP-1

The data doesnt specify the causes of death in every case, but it aligns with known risks such as gastrointestinal issues, pancreatitis, and, in rare instances, kidney or cardiovascular complications

The recently published SURPASS-2 has been conducted in order to compare the efficacy and safety of the three doses of tirzepatide with the GLP-1 agonist semaglutide at an injectable dose of 1 mg in patients with T2DM inadequately controlled with metformin monotherapy

When food problems might signal something else While most GI symptoms on tirzepatide are diet-related and manageable, certain symptoms warrant medical attention

Skin-smoothing efficacy did not differ between the placebo and GSSG sites in the investigators assessment (data not shown)

10.1056/NEJMoa2107519 23 GaoF.LvX.MoZ.MaJ.ZhangQ.YangG.et al (2020)